Evidence map›Paper›PMID 40524293›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Protective effect of Dan Ze mixture against lipotoxic cardiomyopathy through activating B-cell lymphoma-2 adenovirus E1B 19 kDa-interacting protein 3/mitophagy signaling pathway.

Shi Cheng, Chen Jian, Zhang Yufang, Gao Ya, L I Dantong, Yue Shijun, Zhang Yixin

Abstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shi ChengCollege of Basic Medical Sciences, College of Pharmacy, Hebei University of Chinese Medicine, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
Chen JianCollege of Basic Medical Sciences, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
Zhang YufangCollege of Pharmacy, Hebei University of Chinese MediCollege of Basic Medical Sciences, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
Gao YaCollege of Pharmacy, Hebei University of Chinese MediCollege of Basic Medical Sciences, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
L I DantongCollege of Pharmacy, Hebei University of Chinese MediCollege of Basic Medical Sciences, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
Yue ShijunCollege of Pharmacy, Hebei University of Chinese MediCollege of Basic Medical Sciences, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.
Zhang YixinCollege of Pharmacy, Hebei University of Chinese Medicine, International Joint Research Center on Resource Utilization and Quality Evaluation of Traditional Chinese Medicine of Hebei Province, Hebei Technology Innovation Center of Chinese Medicine Formulation, Shijiazhuang 050200, China.

Funding

Hebei graduate student innovation ability funding training project: to Investigate the Protective Effects and Underlying Mechanisms of Zexie Decoction on Lipotoxic Cardiomyopathy, with A Focus on the PGC-1a Signaling Pathway CXZZBS2022096Hebei province natural science fund project: Study on the Mechanism of Danshen Zexie Decoction in Activating Nuclear Factor Erythroid 2-related Factor 2 Signaling Pathway to Trigger 0mi/HtrA2, Restoring Autophagic Flux and Enhancing Metabolism-Related Fatty Liver Disease H2023423064Medical Science Research Project of Hebei Province: the Effect of 23-acetyl Alismol-B on Mitochondrial Function in Palmitic Acid-induced H9c2 Cells Was Investigated based on the Ca-Cyclic Adenosine Monophosphate (cAMP)-Response Element Binding Protein/cAMP Response Element (CREB/CRE)-PGC-1α Signaling Pathway 20221490Scientific Research Project of Hebei Province Administration of Traditional Chinese Medicine: to Explore the Protective Effect and Mechanism of Zexie Decoction on Lipotoxic Cardiomyopathy based on the p-mitogen-activated protein kinases/ Peroxisome proliferator-activated receptor γ coactivator 1-alpha (pMAPK/PGC-1α) Signaling Pathway 2022096
6 · The paper itself

Abstract

objectiveTo investigate the mechanism of Dan Ze mixture (, DZM) in the treatment of lipotoxic cardiomyopathy.

methodsUltra-performance liquid chromatography tandem mass spectrometry was employed to characterize the serum migration constituents of DZM. A lipotoxic cardiomyopathy rat model was established through high-fat diet and intervened by different doses of DZM. The cardiac function was assessed using echocardiography, and hematoxylin and eosin, oil red O, and Masson staining were conducted to evaluate morphological changes, lipid accumulation, and fibrosis in myocardial tissue. Serum myocardial enzyme activity, lipid levels, and lipid content of myocardial tissue were measured, while fluorescent staining and colorimetry were used to assess oxidation levels in myocardial tissue. Mitochondrial membrane potential was detected by 5,5', 6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanineio-dide (JC-1). Transmission electron microscopy was employed to observe ultrastructure and mitochondrial structure changes in myocardial tissue. Fluorescence double staining and colocalization were utilized to observe the binding of autophagosomes and mitochondria, while immunohistochemical staining was used to detect the expression of mitophagy-related proteins. Terminal deoxynucleoitidyl transferase mediated nick end labeling staining was employed for the identification of apoptosis in myocardial tissue, while quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot were utilized for the detection of apoptosis, B-cell lymphoma-2 adenovirus E1B 19 kDa-interacting protein 3 (BNIP3)/ mitophagy signaling pathway-related genes and proteins. In palmitic acid-induced Rat H9C2 cardiomyocytes (H9c2) cells, various cellular parameters including cell viability, lactate dehydrogenase release, apoptosis rate, oxidative stress level, mitochondrial structure and function, and mitophagy level were assessed after the treatment of DZM drug-containing serum for a duration of 24 h. The cellular expressions of BNIP3/mitophagy signaling pathway relevant genes and proteins were further evaluated using qRT-PCR and Western blot techniques.

resultsA total of 295 prototypes (e.g., phenolic acids, quinones, terpenoids) were identified in serum of rats after oral administration of DZM.

conclusionThis study presents preliminary evidence for the therapeutic efficacy of DZM on lipotoxic cardiomyopathy through the activating BNIP3/mitophagy signaling pathway.

Indexed as

CardiomyopathiesDrugs, Chinese HerbalMembrane ProteinsMitophagySignal TransductionAnimalsDiet, High-FatHumansMaleMitochondrial ProteinsRatsRats, Sprague-DawleyBNIP3 protein, ratDrugs, Chinese HerbalMembrane ProteinsMitochondrial ProteinsBcl2/adenovirus E1B gene 19 kDa protein-interacting protein 3Dan Ze mixturelipotoxic cardiomyopathymitochondrial autophagymitophagysignal transduction

Identifiers

PMID40524293
PMCPMC12134320

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.